CV: ↑ BP, tachycardia.
EENT: nasopharyngitis.
GI: constipation, diarrhea, nausea.
GU: urinary tract infection.
Neuro: dizziness, headache.
Misc: ANGIOEDEMA.
The extended-release tablets and extended-release oral suspension are NOT interchangeable and should NOT be combined.
Overactive Bladder
- PO (Adults): 25 mg once daily; may ↑ to 50 mg once daily, if needed, after 4–8 wk.
Renal Impairment
- PO (Adults): eGFR 15–29 mL/min/m2: 25 mg once daily (max dose = 25 mg/day).
Hepatic Impairment
- PO (Adults): Moderate hepatic impairment: 25 mg once daily (max dose = 25 mg/day).
Neurogenic Detrusor Overactivity
- PO (Children ≥3 yr and ≥35 kg): Extended-release tablets: 25 mg once daily; may ↑ to 50 mg once daily, if needed, after 4–8 wk. Extended-release oral suspension (granules): 48 mg once daily; may ↑ to 80 mg once daily, if needed after 4–8 wk.
- PO (Children ≥3 yr and 22–<35 kg): Extended-release oral suspension (granules): 32 mg once daily; may ↑ to 64 mg once daily, if needed after 4–8 wk.
- PO (Children ≥3 yr and 11–<22 kg): Extended-release oral suspension (granules): 24 mg once daily; may ↑ to 48 mg once daily, if needed after 4–8 wk.
Renal Impairment
- PO (Children ≥3 yr and ≥35 kg): eGFR 15–29 mL/min/m2: Extended–release tablets: 25 mg once daily (max dose = 25 mg/day); Extended-release oral suspension (granules): 48 mg once daily (max dose = 48 mg/day).
Renal Impairment
- PO (Children ≥3 yr and 22–<35 kg): eGFR 15–29 mL/min/m2: Extended–release oral suspension (granules): 32 mg once daily (max dose = 32 mg/day).
Renal Impairment
- PO (Children ≥3 yr and 11–<22 kg): eGFR 15–29 mL/min/m2: Extended–release oral suspension (granules): 24 mg once daily (max dose = 24 mg/day).
Hepatic Impairment
- PO (Children ≥3 yr and ≥35 kg): Moderate hepatic impairment: Extended–release tablets: 25 mg once daily (max dose = 25 mg/day); Extended-release oral suspension (granules): 48 mg once daily (max dose = 48 mg/day).
Hepatic Impairment
- PO (Children ≥3 yr and 22–<35 kg): Moderate hepatic impairment: Extended–release oral suspension (granules): 32 mg once daily (max dose = 32 mg/day).
Hepatic Impairment
- PO (Children ≥3 yr and 11–<22 kg): Moderate hepatic impairment: Extended–release oral suspension (granules): 24 mg once daily (max dose = 24 mg/day).
Therapeutic Classification: urinary tract antispasmodics
Pharmacologic Classification: beta-adrenergic agonists
Absorption: 29–35% absorbed following oral administration.
Distribution: Widely distributed.
Metabolism/Excretion: Extensively metabolized, 6% excreted unchanged in urine (25 mg dose), remainder excreted in urine and feces as metabolites.
Half-life: Adults: 50 hr; Children: 26–31 hr.
